Dani Carlo, Poggi Chiara, Agosti Massimo, Bellettato Massimo, Betta Pasqua, Biban Paolo, Corvaglia Luigi, Falsaperla Raffaele, Forcellini Carlo, Gazzolo Diego, Gitto Eloisa, Gizzi Camilla, Lago Paola, Lista Gianluca, Maffei Gianfranco, Mosca Fabio, Napolitano Marcello, Scarpelli Gianfranco, Sandri Fabrizio, Trevisanuto Daniele, Vento Giovanni, Corsini Iuri, Pratesi Simone, Boni Luca
Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Division of Neonatology, Careggi University Hospital of Florence, Florence, Italy.
Ital J Pediatr. 2025 Jan 5;51(1):1. doi: 10.1186/s13052-024-01828-1.
The issue of retreatment with surfactant of infants with respiratory distress syndrome (RDS) has been poorly investigated. Our aim was to identify possible clinical predictors of the need for multiple doses of surfactant in a large cohort of very preterm infants.
Data were analyzed from three previous studies on infants born between 25 and 31 weeks of gestation with RDS who were treated with surfactant.
We studied 448 infants. Among them 306 (68%) were treated with a single dose of surfactant and 142 (32%) were treated with multiple doses. Multivariable mixed effects logistic regression analysis showed that the odd of requiring multiple doses of surfactant was significantly lower in patients with higher gestational age (27-28 vs. 25-26 wks: OR 0.46, 95% C.l. 0.26-0.79; ≥29 vs. 25-26 wks: OR 0.34, 95% C.l. 0.13-0.85; overall P = 0.013), while it increased in infants born to mothers with hypertensive disorders of pregnancy (OR 2.53, 95% C.l. 1.49-4.31; P < 0.001) and with hemodynamically significant PDA (OR 2.74, 95% C.l. 1.66-4.53, P < 0.001).
Gestational age, hypertension in pregnancy, and hemodynamically significant PDA can predict the need for multiple doses of surfactant. Further investigation is needed to evaluate if these sub-groups of preterm infants represent specific phenotypes of RDS who deserve a peculiar surfactant treatment.
关于呼吸窘迫综合征(RDS)婴儿使用表面活性剂进行再次治疗的问题,此前研究较少。我们的目的是在一大群极早产儿中确定多剂量表面活性剂治疗需求的可能临床预测因素。
对之前三项关于妊娠25至31周出生且患有RDS并接受表面活性剂治疗的婴儿的研究数据进行分析。
我们研究了448名婴儿。其中306名(68%)接受了单剂量表面活性剂治疗,142名(32%)接受了多剂量治疗。多变量混合效应逻辑回归分析显示,孕周较大的患者需要多剂量表面活性剂的几率显著降低(27 - 28周与25 - 26周相比:OR 0.46,95%置信区间0.26 - 0.79;≥29周与25 - 26周相比:OR 0.34,95%置信区间0.13 - 0.85;总体P = 0.013),而妊娠高血压疾病母亲所生婴儿的几率增加(OR 2.53,95%置信区间1.49 - 4.31;P < 0.001),以及有血流动力学意义的动脉导管未闭婴儿的几率增加(OR 2.74,95%置信区间1.66 - 4.53,P < 0.001)。
孕周、妊娠高血压和有血流动力学意义的动脉导管未闭可预测多剂量表面活性剂治疗的需求。需要进一步研究来评估这些早产儿亚组是否代表RDS的特定表型,值得进行特殊的表面活性剂治疗。